Home | Welcome to Contract Pharma   
Last Updated Friday, August 1 2014
Print

Amorfix, Cangene In Oncology Development Pact



Published December 6, 2012
Related Searches: Development
Amorfix Life Sciences has entered into a collaboration with CNJ Holdings, a subsidiary of Cangene Corp., for the identification and development of therapeutic antibodies against disease specific epitopes (DSEs) for oncology indications, using Amorfix's ProMIS discovery technology. The terms were not disclosed. 
 
"This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify and develop novel antibody therapeutics for the treatment of cancer," said Dr. Robert Gundel, Amorfix president and chief executive officer. "Establishing partnerships and strategic alliances to accelerate the discovery, development and commercialization of therapeutic antibodies is part of our overall strategy to build our product pipeline."
 
"We are excited about this collaboration with Amorfix which brings new energy to our R&D pipeline development efforts," said John Sedor, Cangene's president and chief executive officer. "This is an opportunity to leverage our core competencies to accelerate the development of therapeutic antibodies to novel targets in the oncology space.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On